Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 217-225

  Lilitkarntakul, Pajaree ^a   Dhaun, Neeraj ^a,b   Melville, Vanessa ^a   Blackwell, Scott ^b   Talwar, Dinesh K ^c   Liebman, Barbara ^a   Asai, Takae ^a   Pollock, Jennifer ^d   Goddard, Jane ^b   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Asymmetric dimethylarginine; Chronic kidney disease; Endothelin; Inflammation; Nitric oxide; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; ISOPROSTANE DERIVATIVE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; UREMIA;

ADULT; ANALYSIS OF VARIANCE; ARGININE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CAROTID ARTERIES; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMORBIDITY; COMPLIANCE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; FEMORAL ARTERY; GLOMERULAR FILTRATION RATE; HUMANS; ISOPROSTANES; KIDNEY; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; PULSATILE FLOW; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; UREMIA; VASODILATION;

EID: 79955539810     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.045     Document Type: Article

References (50)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
2. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
3. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006, 70:26-33.
4. Gusbeth-Tatomir P., Covic A. Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res 2007, 30:97-107.
5. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
6. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006, 17:943-955.
7. Guerin A.P., Pannier B., Metivier F., Marchais S.J., London G.M. Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:635-641.
8. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434-2439.
9. Guerin A.P., Blacher J., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001, 103:987-992.
10. Wilkinson I.B., Franklin S.S., Cockcroft J.R. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004, 44:112-116.
11. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004, 15:1983-1992.
12. van Guldener C., Lambert J., Janssen M.J., Donker A.J., Stehouwer C.D. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transpl 1997, 12(Suppl. 2):14-18.
13. van Guldener C., Janssen M.J., Lambert J., Steyn M., Donker A.J., Stehouwer C.D. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transpl 1998, 13:1782-1786.
14. Perticone F., Ceravolo R., Pujia A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191-196.
15. Wang M.C., Tsai W.C., Chen J.Y., Huang J.J. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005, 45:494-501.
16. Thambyrajah J., Landray M.J., McGlynn F.J., Jones H.J., Wheeler D.C., Townend J.N. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000, 83:205-209.
17. Matsuda N., Takei T., Fujiu A., Ogawa T., Nitta K. Arterial stiffness in patients with non-diabetic chronic kidney disease (CKD). J Atheroscl Thromb 2009, 16:57-62.
18. Shinohara K., Shoji T., Tsujimoto Y., et al. Arterial stiffness in predialysis patients with uremia. Kidney Int 2004, 65:936-943.
19. Annuk M., Lind L., Linde T., Fellstrom B. Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transpl 2001, 16:302-306.
20. Perticone F., Maio R., Tripepi G., Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004, 110:821-825.
21. Yilmaz M.I., Saglam M., Caglar K., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006, 47:42-50.
22. Anonymous K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
23. O'Brien E., Mee F., Atkins N., Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996, 1:55-61.
24. Wilkinson I.B., Fuchs S.A., Jansen I.M., et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998, 16:2079-2084.
25. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
26. Blackwell S., O'Reilly D.S., Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest 2007, 37:364-371.
27. Strachan F.E., Spratt J.C., Wilkinson I.B., Johnston N.R., Gray G.A., Webb D.J. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999, 33:581-585.
28. Mafham M.M., Niculescu-Duvaz I., Barron J., et al. A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. Nephron 2007, 106:c104-c112.
29. Froissart M., Rossert J., Jacquot C., Paillard M., Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763-773.
30. Ilyas B., Dhaun N., Markie D., et al. Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease. QJM 2009, 102:183-191.
31. Sengstock D., Sands R.L., Gillespie B.W., et al. Dominance of traditional cardiovascular risk factors over renal function in predicting arterial stiffness in subjects with chronic kidney disease. Nephrol Dial Transpl 2009.
32. Borawski J., Mysliwiec M. The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients. Nephron 2001, 89:381-383.
33. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
34. Romao J.E., Haiashi A.R., Elias R.M., et al. Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol 2006, 26:59-66.
35. Stam F., van Guldener C., Schalkwijk C.G., ter Wee P.M., Donker A.J., Stehouwer C.D. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transpl 2003, 18:892-898.
36. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
37. Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59:824-833.
38. Fleck C., Janz A., Schweitzer F., Karge E., Schwertfeger M., Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001, 78:S14-S18.
39. Young J.M., Terrin N., Wang X., et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009.
40. Koyama H., Tabata T., Nishzawa Y., Inoue T., Morii H., Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989, 1:991-992.
41. Saito Y., Kazuwa N., Shirakami G., et al. Endothelin in patients with chronic renal failure. J Cardiovas Pharmacol 1991, 17(Suppl. 7):S437-S439.
42. Stenvinkel P., Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it?. Blood Purif 2005, 23:72-78.
43. Soveri I., Lind L., Wikstrom B., Zilmer M., Zilmer K., Fellstrom B. Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels. Nephron 2007, 106:c180-c186.
44. Fujii H., Takiuchi S., Kawano Y., Fukagawa M. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens 2008, 21:650-656.
45. Demuth K., Blacher J., Guerin A.P., et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transpl 1998, 13:375-383.
46. Heintz B., Dorr R., Gillessen T., et al. Do arterial endothelin 1 levels affect local arterial stiffness?. Am Heart J 1993, 126:987-989.
47. Karakitsos D., Patrianakos A.P., Parthenakis F.I., et al. Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease. ASAIO J 2007, 53:343-350.
48. Yilmaz M.I., Saglam M., Caglar K., et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005, 80:1660-1666.
49. Sibal L., Agarwal S.C., Schwedhelm E., Luneburg N., Boger R.H., Home P.D. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol 2009, 8:27.
50. Oliver J.J., Webb D.J. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003, 23:554-566.